p53 Status and the Efficacy of Cancer Therapy in Vivo
- 4 November 1994
- journal article
- other
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 266 (5186) , 807-810
- https://doi.org/10.1126/science.7973635
Abstract
The therapeutic responsiveness of genetically defined tumors expressing or devoid of the p53 tumor suppressor gene was compared in immunocompromised mice. Tumors expressing the p53 gene contained a high proportion of apoptotic cells and typically regressed after treatment with gamma radiation or adriamycin. In contrast, p53-deficient tumors treated with the same regimens continued to enlarge and contained few apoptotic cells. Acquired mutations in p53 were associated with both treatment resistance and relapse in p53-expressing tumors. These results establish that defects in apoptosis, here caused by the inactivation of p53, can produce treatment-resistant tumors and suggest that p53 status may be an important determinant of tumor response to therapy.Keywords
This publication has 16 references indexed in Scilit:
- p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lensNature, 1994
- p53-Dependent apoptosis suppresses tumor growth and progression in vivoCell, 1994
- Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutationsNature Genetics, 1994
- p53-dependent apoptosis modulates the cytotoxicity of anticancer agentsCell, 1993
- Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.The Journal of cell biology, 1992
- Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesisNature, 1992
- Effects of an Rb mutation in the mouseNature, 1992
- Requirement for a functional Rb-1 gene in murine developmentNature, 1992
- Induction of apoptosis in fibroblasts by c-myc proteinCell, 1992
- p53 Mutations in Human CancersScience, 1991